Schering Brokers Extension For Golimumab Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Under agreement with co-developer Centocor, Schering will have exclusive worldwide marketing rights 15 years beyond expected launch date.
You may also be interested in...
J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.
J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.
J&J Could File “New Gold Standard” In Anti-TNF Therapy By Late 2007
CNTO 148 is in Phase III for RA, ankylosing spondylitis and psoriatic arthritis.